发现了一种新的选择性ERAP1抑制剂,用于治疗依赖的癌症
Francesca Bufalieri1, Antonino Cucinotta1, Silvia Cammarone2
1Department of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy.
概括
一种新的化合物,丁-6-one (N1),可以选择性地抑制ERAP1,这是子 (HH) 途径癌症的点,如脑髓母细胞瘤 (MB). 通过减少瘤生长和改善生存率,N1在治疗HH-MB方面表现有前途.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 刺 (HH) 信号通路与各种癌症有关,包括儿科髓母细胞瘤 (MB).
- HH-MB异质且耐治疗,需要新的治疗策略.
- 细胞内膜网膜氨基酶1 (ERAP1) 是HH-MB的潜在治疗标,但缺乏有效的抑制剂.
研究的目的:
- 确定和描述一种用于治疗HH-MB的新型,选择性的ERAP1抑制剂.
- 为了阐明在HH途径内发现的ERAP1抑制剂的作用机制.
主要方法:
- 查ERAP1抑制剂并识别康-6-一 (N1).
- 研究N1与ERAP1的结合及其对HH通路组件的影响 (USP47,βTrCP,Gli1).
- 评估N1在HH-MB细胞系和小鼠模型中的疗效,包括其透血脑屏障.
主要成果:
- 康-6-one (N1) 被确定为一种选择性的ERAP1抑制剂,直接结合ERAP1.1.
- N1通过损害其与USP47的关联来破坏ERAP1的功能,从而增加βTrCP稳定性和Gli1降解.
- 在实验室和体内,N1显著抑制了HH-MB生长,在小鼠模型中改善了生存率,并跨越了血脑屏障.
结论:
- 丁-6-one (N1) 是一种强大的ERAP1抑制剂,对依赖HH的癌症具有治疗潜力.
- N1代表了一种有前途的新疗法选择,用于脑髓母细胞瘤,特别是HH-MB.
- 用N1针对ERAP1提供了一种新的策略,以克服HH-MB的治疗耐药性.
相关概念视频
02:33Hedgehog Signaling Pathway
9.8K
The Hedgehog gene (Hh) was first discovered due to its control of the growth of disorganized, hair-like bristles phenotype in Drosophila, much like hedgehog spines. Hh plays a crucial role in the development of organs and the maintenance of homeostasis in both invertebrates and vertebrates. However, while Drosophila has only one Hh protein, mammals have multiple functional Hedgehog proteins - Sonic (Shh), Desert (Dhh), and Indian Hedgehog (Ihh). All of these homologous proteins have adapted to...
9.8K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K